Funded Biotechnology Startups in Berkeley
The disclosed funding amounts in this Berkeley biotechnology slice cluster tightly below the top end, with Carmot Therapeutics’ $150M round (2023-05-25) th…
The disclosed funding amounts in this Berkeley biotechnology slice cluster tightly below the top end, with Carmot Therapeutics’ $150M round (2023-05-25) the largest disclosed amount. The next-largest disclosed rounds sit at $125M (Caribou Biosciences, 2023-07-13) and $90M (Perfect Day, 2024-01-05), while most other disclosed entries fall into lower- and mid–tens of millions. One clear outlier on the downside is BioGlyph’s “undisclosed” round (2024-08-06), which breaks the otherwise disclosed-amount comparison.
Dates span 2020-12-01 (Newomics) through 2025-11-03 (Kyverna Therapeutics), and several rounds cluster in 2023: multiple entries from May–October 2023 include Carmot Therapeutics ($150M, 2023-05-25), Caribou Biosciences ($125M, 2023-07-13), and Pow.bio ($10M, 2023-10-04). Stage labeling is mixed: “Series Unknown” appears in 7 of 20 rows, and “Seed” appears in 4 of 20 rows, with additional presence of Series A (4 of 20 rows) and later stages such as Series E (2 of 20 rows). Geography is consistently Berkeley, California across all 20 rows.
Most recent rounds
20 shownRelated listings
Frequently asked
Which company has the largest disclosed round in this Berkeley biotechnology list, and how far ahead is it of the next-largest disclosed amount?
Carmot Therapeutics holds the largest disclosed amount at $150M on 2023-05-25. The next-largest disclosed rounds are $125M (Caribou Biosciences, 2023-07-13) and $90M (Perfect Day, 2024-01-05), so the top round is materially above the rest.
Do the most recent rounds concentrate in a narrow time window (e.g., within the last ~1 year) or spread out?
The most recent entry is Kyverna Therapeutics on 2025-11-03, followed by two more entries in late 2024 (EditPep 2024-12-19 at $8M; SonALAsense 2024-12-12 at $46M). Beyond that, the list shows heavier concentration in 2023, including multiple high-ticket rounds such as Carmot Therapeutics ($150M, 2023-05-25) and Caribou Biosciences ($125M, 2023-07-13).
Is “Series Unknown” common enough to affect how analysts should segment these funding rounds by stage?
Yes. “Series Unknown” appears in 7 of 20 rows, including Kyverna Therapeutics (2025-11-03, $25M) and SonALAsense (2024-12-12, $46M). Seed shows up in 4 of 20 rows (e.g., MeliBio $6M on 2022-03-17; Fauna Bio $9M on 2021-09-21), and Series A also appears 4 of 20 rows (e.g., Actym Therapeutics $26M on 2023-10-18; Pow.bio $10M on 2023-10-04).
Are there notable outliers beyond the top end, such as very small disclosed rounds or undisclosed amounts?
BioGlyph’s 2024-08-06 round is “undisclosed,” which prevents direct sizing in comparisons. Among disclosed amounts, the smallest shown is $1M (Novel Farms, Inc., 2023-09-28; and Flightpath Biosciences, 2023-02-15), creating a wide spread from the $150M max to the $1M floor.
Within this dataset, are later-stage rounds (Series B/E) clustered around specific years, or distributed?
Later stages appear, but not densely: Series E is present twice (Perfect Day $90M on 2024-01-05; Carmot Therapeutics $150M on 2023-05-25). Series B appears once (Valitor $28M on 2022-10-05), while earlier labels like Seed and Series A show more repetition across 2021–2023 (e.g., Fauna Bio $9M on 2021-09-21; Nodexus $30M on 2021-12-16; Actym Therapeutics $26M on 2023-10-18).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.